Long- Versus Short-acting Beta 2-agonists. Implications for Drug Therapy

Overview

Journal Drugs

Specialty Pharmacology

Date 1994 Feb 1

PMID 7512898

Citations 8

Authors

L P Boulet

Affiliations

Soon will be listed here.

Citing Articles

National athletic trainers' association position statement: preventing sudden death in sports.

Casa D, Guskiewicz K, Anderson S, Courson R, Heck J, Jimenez C J Athl Train. 2012; 47(1):96-118.

PMID: 22488236 PMC: 3418121. DOI: 10.4085/1062-6050-47.1.96.

2003 canadian asthma consensus guidelines executive summary.

Becker A, Lemiere C, Berube D, Boulet L, Ducharme F, Fitzgerald M Allergy Asthma Clin Immunol. 2010; 2(1):24-38.

PMID: 20529217 PMC: 3238210. DOI: 10.1186/1710-1492-2-1-24.

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.

Walters E, Gibson P, Lasserson T, Walters J Cochrane Database Syst Rev. 2007; (1):CD001385.

PMID: 17253458 PMC: 10849111. DOI: 10.1002/14651858.CD001385.pub2.

National Athletic Trainers' Association position statement: management of asthma in athletes.

Miller M, Weiler J, Baker R, Collins J, DAlonzo G J Athl Train. 2005; 40(3):224-45.

PMID: 16284647 PMC: 1250269.

Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003.

Becker A, Lemiere C, Berube D, Boulet L, Ducharme F, Fitzgerald M CMAJ. 2005; 173(6 Suppl):S3-11.

PMID: 16157733 PMC: 1329945.

References

Malo J, Cartier A, Trudeau C, Ghezzo H, Gontovnick L . Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis. 1990; 142(5):1147-52. DOI: 10.1164/ajrccm/142.5.1147. View

Tattersfield A . Effect of beta-agonists and anticholinergic drugs on bronchial reactivity. Am Rev Respir Dis. 1987; 136(4 Pt 2):S64-8. DOI: 10.1164/ajrccm/136.4_Pt_2.S64. View

Poole C, Lanes S, Walker A . Fenoterol and fatal asthma. Lancet. 1990; 335(8694):920. DOI: 10.1016/0140-6736(90)90522-7. View

van Schayck C, Graafsma S, Visch M, Dompeling E, van Weel C, van Herwaarden C . Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol. 1990; 86(5):793-800. DOI: 10.1016/s0091-6749(05)80185-x. View

Petty T, BRANDON M, Busse W, Chervinsky P, Schoenweter W, Beaupre A . A comparison of oral procaterol and albuterol in reversible airflow obstruction. Am Rev Respir Dis. 1988; 138(6):1504-9. DOI: 10.1164/ajrccm/138.6.1504. View

Lofdahl C, Chung K . Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J. 1991; 4(2):218-26. View

Simons F, Soni N, Watson W, Becker A . Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma. J Allergy Clin Immunol. 1992; 90(5):840-6. DOI: 10.1016/0091-6749(92)90110-n. View

Boulet L, Turcotte H, Tennina S . Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol. 1989; 83(5):882-7. DOI: 10.1016/0091-6749(89)90101-2. View

Chetta A, Del Donno M, Maiocchi G, Pisi G, Moretti D, Olivieri D . Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. Ann Allergy. 1993; 70(2):171-4. View

10.

Shepherd G, Hetzel M, Clark T . Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest. 1981; 75(2):215-7. DOI: 10.1016/0007-0971(81)90057-7. View

11.

Wilkinson J, Roberts J, Bradding P, Holgate S, Howarth P . Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ. 1992; 305(6859):931-2. PMC: 1883565. DOI: 10.1136/bmj.305.6859.931. View

12.

Malo J, Ghezzo H, Trudeau C, Larcheveque J, Cartier A . Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immunol. 1992; 89(2):567-74. DOI: 10.1016/0091-6749(92)90324-u. View

13.

Kraan J, Koeter G, vd Mark T, SLUITER H, de Vries K . Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985; 76(4):628-36. DOI: 10.1016/0091-6749(85)90786-9. View

14.

Rabe K, Chung K . The challenge of long-acting beta-adrenoceptor agonists. Respir Med. 1991; 85(1):5-9. DOI: 10.1016/s0954-6111(06)80203-9. View

15.

Hargreave F, Dolovich J, Newhouse M . The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol. 1990; 85(6):1098-111. DOI: 10.1016/0091-6749(90)90056-a. View

16.

OConnor B, Aikman S, Barnes P . Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med. 1992; 327(17):1204-8. DOI: 10.1056/NEJM199210223271704. View

17.

Nijkamp F, Engels F, Henricks P, van Oosterhout A . Mechanisms of beta-adrenergic receptor regulation in lungs and its implications for physiological responses. Physiol Rev. 1992; 72(2):323-67. DOI: 10.1152/physrev.1992.72.2.323. View

18.

Flatt A, Crane J, Purdie G, Kwong T, Beasley R, Burgess C . The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation. Postgrad Med J. 1990; 66(772):98-101. PMC: 2429517. DOI: 10.1136/pgmj.66.772.98. View

19.

Brogden R, Faulds D . Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991; 42(5):895-912. DOI: 10.2165/00003495-199142050-00010. View

20.

Ramsdale E, Otis J, KLINE P, Gontovnick L, Hargreave F, OByrne P . Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. Am Rev Respir Dis. 1991; 143(5 Pt 1):998-1001. DOI: 10.1164/ajrccm/143.5_Pt_1.998. View